SCHEMBL746641

SCHEMBL746641

O=C(O)/C=C/CCCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.52
PPARA Q07869 6/20 0.52
PPARD Q03181 4/20 0.52
TOP1 P11387 3/20 0.52
CYP19A1 P11511 3/20 0.52
KMT2A Q03164 3/20 0.52
F7 P08709 3/20 0.52
F3 P13726 3/20 0.52
ALDH1A1 P00352 2/20 0.52
ADORA3 P0DMS8 2/20 0.52
PTGS1 P23219 2/20 0.52
RXRA P19793 1/20 0.52
OXER1 Q8TDS5 1/20 0.52
MAPT P10636 3/20 0.50
FABP4 P15090 3/20 0.50
BLM P54132 3/20 0.50
HSD17B10 Q99714 3/20 0.50
USP2 O75604 2/20 0.50
LMNA P02545 2/20 0.50
ALOX15 P16050 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23191724 1.00 PPARG (0.52) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL746642 1.00 PPARG (0.52) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL10755621 0.93 PPARG (0.58) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL747518 0.93 PPARG (0.58) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL747519 0.93 PPARG (0.58) PPARGPPARAPPARDTOP1CYP19A1
Traumatic Acid SCHEMBL2513605 0.91 MAPT (0.61) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL908413 0.91 MAPT (0.61) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL22032688 0.91 MAPT (0.61) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL22128451 0.91 MAPT (0.61) PPARGPPARAPPARDTOP1CYP19A1
SCHEMBL3021999 0.91 MAPT (0.61) PPARGPPARAPPARDTOP1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110498912-B Curable unsaturated crystalline polyester powder and process for preparing the same 施乐公司 2023-09-01 CN claimed
EP-3569634-B1 CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME XEROX CORP (US) 2023-04-19 EP claimed
CN-106592237-B Unsaturated acid modified epoxy resin universal sizing agent for carbon fibers, preparation method and application 中国石油化工股份有限公司 2020-09-04 CN claimed
CN-106592236-B Small tow universal carbon fiber sizing agent, preparation method and application thereof 中国石油化工股份有限公司 2020-09-04 CN claimed
US-10703859-B2 Compositions comprising unsaturated crystalline polyester for 3D printing XEROX CORPORATION (US) 2020-07-07 US claimed
US-10689673-B2 Bioconversion process for producing nylon-7, nylon-7,7 and polyesters INVISTA NORTH AMERICA S.A.R.L. (US) 2020-06-23 US claimed
US-10655025-B2 Curable unsaturated crystalline polyester powder and methods of making the same XEROX CORPORATION (US) 2020-05-19 US claimed
US-20190352455-A1 COMPOSITIONS COMPRISING UNSATURATED CRYSTALLINE POLYESTER FOR 3D PRINTING Genesee Valley Innovations, LLC 2019-11-21 US claimed
US-20190352521-A1 CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME Genesee Valley Innovations, LLC 2019-11-21 US claimed
EP-3569634-A1 CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME Xerox Corporation (US) 2019-11-20 EP claimed
EP-3569633-A1 COMPOSITIONS COMPRISING UNSATURATED CRYSTALLINE POLYESTER FOR 3D PRINTING Xerox Corporation (US) 2019-11-20 EP claimed
US-9896702-B2 Methods, reagents and cells for biosynthesizing compounds INVISTA NORTH AMERICA S.A.R.L. (US) 2018-02-20 US claimed
EP-3155106-A2 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUND Invista Technologies S.à.r.l. (CH) 2017-04-19 EP claimed
WO-2015195611-A2 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUND INVISTA TECHNOLOGIES S.À.R.L. (CH) 2015-12-23 WO claimed
US-20150361458-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUND INV NYLON CHEMICALS AMERICAS, LLC 2015-12-17 US claimed
EP-2823032-A1 RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE Lygos, Inc. (US) 2015-01-14 EP claimed
WO-2013134424-A1 RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE LYGOS, INC. (US) 2013-09-12 WO claimed
US-12637680-B2 Recombinant host cells for the production of malonate LYGOS, INC. (US) 2026-05-26 US disclosed
WO-2009074667-A1 LUBRICATING OIL COMPOSITION SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 2009-06-18 WO disclosed
US-3983230-A HALF ESTERS WITH DICARBOXYLIC ACIDS, MEDICAMENTS SHIONOGI & CO., LTD. (JA) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637680-B2 Recombinant host cells for the production of malonate DCXR, ETV1, LYPLA2 PPARG 2567/4885PPARA 1054/4885PPARD 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.